Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- 5-Camp Battle Heating Up in HIF-PH Market; Evrenzo, Duvroq Neck-and-Neck for Top Spot
May 19, 2021
- Fujifilm, BlueRock Form Strategic Alliance to Develop iPSC Therapies for Ocular Diseases
May 19, 2021
- Tord Labuda Becomes Interim Chief of LEO Pharma Japan, Sakurai Resigns
May 19, 2021
- Reps’ Face-to-Face Meetings for GPs Back to Prepandemic Levels in March: Intage
May 19, 2021
- Nichi-Iko Refrains from June Listing to Focus on Re-Supply of Existing Drugs
May 18, 2021
- Nipro Pharma to Build New Injectable Plant in Shiga
May 18, 2021
- Takeda, Fujitsu, NCC Join Forces to Analyze Journey of Ovarian Cancer Patients
May 18, 2021
- Big 4 Wholesalers’ Operating Margin Sinks to 0.49% on COVID-19, Competition
May 17, 2021
- 2 Ono Employees Admits Bribery Charges over Onoact Prescriptions
May 17, 2021
- Eisai, NCC Strike Drug Discovery Deal on Rare/Refractory Cancers
May 17, 2021
- Astellas/Seagen’s ADC Enfortumab Vedotin Gets Priority Review in Japan
May 17, 2021
- Astellas, Kyoto University VC Pair Up on Cross-Disciplinary Drug Discovery
May 17, 2021
- FY2020 Sales of 7 Major Japan Drug Makers Slip 2.7% on COVID-19, Price Woes: Tally
May 14, 2021
- Japan Ethical Drug Sales Up 5.7% in March: Crecon
May 14, 2021
- Opdivo Top-Selling Drug in Japan in April: Encise
May 14, 2021
- Otsuka’s Q1 Pharma Sales Down 5.0% on Japan Dip, 4 Global Brands Grow
May 14, 2021
- Daiichi Sankyo Seeks Central Neuropathic Pain Use for Tarlige
May 14, 2021
- Ono Cuts Opdivo Guidance to 110 Billion Yen for FY2021
May 14, 2021
- Chugai Presses on with Japan Development of 3 COVID-19 Drugs, Aims for Antibody Cocktail Filing in 2021: President
May 14, 2021
- Mitsubishi Tanabe Incurs Operating Loss 2 Years Running as Parkinson’s Write-Down Weighs
May 13, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…